Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivosidenib Plus mFOLFOXIRI and Celecoxib as a Treatment for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients: a Phase II Study

NCT07809893 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07809893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07809893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivosidenib Plus mFOLFOXIRI and Celecoxib as a Treatment for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients: a Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
August 10, 2026
Completion date
June 30, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer